Our Partners











Clotting factor concentrates

NUWIQ, another recombinant factor VIII option

With the approval of Nuwiq by Health Canada and its success in obtaining a share of the factor VIII market in provinces served by Canadian Blood Services, Hemophilia Today sat down with Lidia Cosentino, Ph.D., director of medical and scientific affairs at Octapharma Canada, and Dr. Anthony K. C. Chan, pediatrician and co-director of the hemophilia program at Hamilton Health Sciences Centre, to learn more about this coagulation therapy.

CLICK HERE for the full interview.


Bayer introduces KOVALTRY to replace Kogenate FS in Canada

Bayer introduces Kovaltry to replace Kogenate FS in Canada Kogenate and Kogenate FS have been used in Canada to treat hemophilia A for almost a quarter-century. Their manufacturer, Bayer, is now replacing Kogenate FS with Kovaltry in the Canadian marketplace.

Hemophilia Today met with Mohammed Mahdi, medical and scientific advisor in the Hematology Branch at Bayer Canada, and Jayson Stoffman, medical director at the Manitoba Bleeding Disorders Program and past-president of the Association of Hemophilia Clinic Directors of Canada, to learn more about Kovaltry.

CLICK HERE to read the interview.



ELOCTATE, a longer half-life factor VIII, approved by Health Canada

Eloctate™, a recombinant factor VIII concentrate manufactured by Biogen, was approved by Health Canada on August 26, 2014. It is indicated in adults and children with hemophilia A for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes and for control of bleeding episodes.

Hemophilia Today (HT) interviewed two physicians who were closely involved with the development and clinical trials of Eloctate.

CLICK HERE to read the interview.



ALPROLIX, a longer half-life factor IX, approved by Health Canada

Alprolix™, a recombinant factor IX concentrate manufactured by Biogen Idec, was approved by Health Canada March 21, 2014 and by the U.S. FDA a week later. It is indicated in adults and children with hemophilia B for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes and for control of bleeding episodes.

Hemophilia Today (HT) interviewed two physicians who were closely involved with the development and clinical trials of Alprolix.

CLICK HERE for the full interview.